Literature DB >> 15265773

Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors.

Sagar Sengupta1, Bohdan Wasylyk.   

Abstract

The p53 tumor suppressor plays a key role in protection from the effects of different physiological stresses (DNA damage, hypoxia, transcriptional defects, etc.), and loss of its activity has dire consequences, such as cancer. Its activity is finely tuned through interactions with other important regulatory circuits in the cell. Recently, striking evidence has emerged for crosstalk with another class of important regulators, the steroid hormone receptors, and in particular the glucocorticoid (GR), androgen (AR), and estrogen (ER) receptors. These receptors are important in maintaining homeostasis in response to internal and external stresses (GR) and in the development, growth, and maintenance of the male and female reproductive systems (AR and ER, respectively). We review how p53 interacts closely with these receptors, to the extent that they share the same E3 ubiquitin ligase, the MDM2 oncoprotein. We discuss the different physiological contexts in which such interactions occur, and also how these interactions have been undermined in various pathological situations. We will describe future areas for research, with special emphasis on GR, and how certain common features, such as cytoplasmic anchoring of p53 by the receptors, may become targets for the development of therapeutic interventions. Given the importance of GR in inflammation, erythropoiesis, and autoimmune diseases, and the importance of AR and ER in prostate and breast cancer (respectively), the studies on p53 interactions with the steroid receptors will be an important domain in the near future.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265773     DOI: 10.1196/annals.1321.005

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

1.  A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.

Authors:  Zhihe Liu; Guanghua Wan; Christopher Heaphy; Marco Bisoffi; Jeffrey K Griffith; Chien-An A Hu
Journal:  Mol Cell Biochem       Date:  2006-11-21       Impact factor: 3.396

2.  Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor gene.

Authors:  William W Au; Salama Abdou-Salama; Ayman Al-Hendy
Journal:  Gynecol Oncol       Date:  2006-11-29       Impact factor: 5.482

Review 3.  Sequential gene regulatory events leading to glucocorticoid-evoked apoptosis of CEM human leukemic cells:interactions of MAPK, MYC and glucocorticoid pathways.

Authors:  M S Webb; A L Miller; T L Howard; B H Johnson; S Chumakov; Y Fofanov; T Nguyen-Vu; C Y Lin; E B Thompson
Journal:  Mol Cell Endocrinol       Date:  2018-03-26       Impact factor: 4.102

4.  Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions.

Authors:  Susan Holbeck; Jianjun Chang; Anne M Best; Angie L Bookout; David J Mangelsdorf; Elisabeth D Martinez
Journal:  Mol Endocrinol       Date:  2010-04-07

5.  MDM2 regulates estrogen receptor α and estrogen responsiveness in breast cancer cells.

Authors:  Kyounghyun Kim; Robert Burghardt; Rola Barhoumi; Syng-Ook Lee; Xinyi Liu; Stephen Safe
Journal:  J Mol Endocrinol       Date:  2011-02-15       Impact factor: 5.098

6.  Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.

Authors:  Natalia V Narizhneva; Natalia D Tararova; Petro Ryabokon; Inna Shyshynova; Anatoly Prokvolit; Pavel G Komarov; Andrei A Purmal; Andrei V Gudkov; Katerina V Gurova
Journal:  Cell Cycle       Date:  2009-12-13       Impact factor: 4.534

7.  The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis.

Authors:  Lilian Varricchio; Anna Rita Migliaccio
Journal:  Am J Blood Res       Date:  2014-12-15

8.  Regulation of peroxisome proliferator-activated receptor-alpha by MDM2.

Authors:  Lakshmi Gopinathan; Daniel B Hannon; Jeffrey M Peters; John P Vanden Heuvel
Journal:  Toxicol Sci       Date:  2008-12-22       Impact factor: 4.849

9.  L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells.

Authors:  E Ayroldi; M G Petrillo; A Bastianelli; M C Marchetti; S Ronchetti; G Nocentini; L Ricciotti; L Cannarile; C Riccardi
Journal:  Cell Death Differ       Date:  2014-08-29       Impact factor: 15.828

10.  Prepubertal physical activity up-regulates estrogen receptor beta, BRCA1 and p53 mRNA expression in the rat mammary gland.

Authors:  M Wang; B Yu; K Westerlind; R Strange; G Khan; D Patil; K Boeneman; L Hilakivi-Clarke
Journal:  Breast Cancer Res Treat       Date:  2008-05-31       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.